Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

2 recruiting3 with results

Enrollment Performance

Analytics

Phase 2

2(40.0%)

Phase 3

1(20.0%)

Phase 1

1(20.0%)

N/A

1(20.0%)

5Total

Phase 2(2)

Phase 3(1)

Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05789589Phase 1Recruiting

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

Role: collaborator

NCT05756985Recruiting

Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue

Role: collaborator

NCT02921022Not ApplicableActive Not Recruiting

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

Role: collaborator

NCT02682316Phase 3Completed

Negative Pressure Wound Therapy in Post-Operative Incision Management

Role: collaborator

NCT03274661Phase 2Completed

Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors

Role: collaborator

NCT02525653Phase 2Completed

Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

Role: collaborator

All 6 trials loaded